Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference103 articles.
1. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma;Jakubowiak;Blood,2012
2. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma;Korde;JAMA Oncol,2015
3. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes;Landgren;J Intern Med,2017
4. Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient;Landgren;Cytometry B Clin Cytom,2016
5. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis;Landgren;Bone Marrow Transplant,2016
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions;Current Oncology Reports;2024-04-27
2. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group;Cancers;2024-02-29
3. Risk Stratification Including Measurable Residual Disease in Multiple Myeloma;Cancer Consult;2023-11-18
4. Aiming for the cure in myeloma: Putting our best foot forward;Blood Reviews;2023-11
5. Flow Cytometry in Diagnosis, Prognostication, and Monitoring of Multiple Myeloma and Related Disorders;Clinics in Laboratory Medicine;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3